Results 131 to 140 of about 143,635 (330)

Different consequences of the treatment of osteoarthritis in gastrointestinal comorbidity with exocrine pancreatic insufficiency

Family Medicine & Primary Care Review, 2021
Iryna Halabitska, Liliya Babinets
doaj   +1 more source

Gout and NLRP3 Inflammasome Biology

Arthritis &Rheumatology, EarlyView.
This review describes the three broad stages of acute inflammation in the context of gout: initiation, leucocyte mobilization, and self‐resolution. A typical case of a gout flare is presented. The role of the NLRP3 inflammasome in acute monosodium urate crystal–induced inflammation is reviewed in detail.
Raewyn Poulsen, Nicola Dalbeth
wiley   +1 more source

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica

Arthritis &Rheumatology, EarlyView.
Objective The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) treatment in patients with glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC dose and disease activity at week 24. This study aimed to assess relapse rates after stopping TCZ treatment in patients achieving remission at week 24.
Baptiste Chevet, Aghiles Souki, Emmanuel Nowak, Guillermo Carvajal‐Alegria, Emmanuelle Dernis, Christophe Richez, Marie‐Elise Truchetet, Daniel Wendling, Eric Toussirot, Aleth Perdriger, Jacques‐Eric Gottenberg, Renaud Felten, Bruno Fautrel, Anne Lohse, Laurent Chiche, Pascal Hilliquin, Catherine Le Henaff, Benjamin Dervieux, Guillaume Direz, Isabelle Chary‐Valckenaere, Divi Cornec, Dewi Guellec, Thierry Marhadour, Alain Saraux, Valérie Devauchelle‐Pensec   +24 more
wiley   +1 more source

Preventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity

Gut and Liver, 2014
Background/AimsThe use of proton pump inhibitors or misoprostol is known to prevent the gastrointestinal complications of nonsteroidal anti-inflammatory drugs (NSAIDs).
doaj   +1 more source

Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

Arthritis &Rheumatology, Accepted Article.
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun, Yu Wang, Yongjing Cheng, Dongmei Guo, Jiankang Hu, Dongzhou Liu, Zhengnan Gao, Changgui Li, Yibing Lu, Xiaodan Kong, Yu Liu, Zhenyu Jiang, Bin Yi, Hongfeng Zhang, Baijie Xu, Shihao Yu, Rieko Kokan, Kohei Ishikawa, Mikiko Kawakatsu, Zhuoli Zhang   +19 more
wiley   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Effective treatment of multifocal aggressive fibromatosis with low-dose chemotherapy

The Turkish Journal of Pediatrics, 2006
Desmoid tumor (aggressive fibromatosis), as a member of a group of borderline neoplasms, is a rare tumor of fibroblastic origin that remains difficult to treat.
Kudret Caglar, Hasan Ozyönüm, Minel Akalin, Sevim Balci   +3 more
doaj  

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

Hepatology, EarlyView., 2022
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan, André Megarbane, Aziz Chouchane, Deepak Karthik, Ramzi Temanni, Atilio Reyes Romero, Huiying Hua, Chun Pan, Xixi Chen, Murugan Subramanian, Chadi Saad, Hamdi Mbarek, Cybel Mehawej, Eliane Chouery, Sirin W. Abuaqel, Alexander Dömling, Sami Remadi, Cesar Yaghi, Pu Li, Lotfi Chouchane   +19 more
wiley   +1 more source